ribosomal protein L10 pseudogene 17Genealiases: []
Q-omics provides the consensus-scored RPL10P17 profile across patient tissues and cancer cell-line models. RPL10P17 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RPL10P17 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, RPL10P17 RNA expression shows 5,766 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, PRAD, and STAD as cancer lineages where RPL10P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10P17 survival associations across molecular data types. RPL10P17 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10P17 RNA expression–survival associations across cancer types. High RPL10P17 expression shows unfavorable associations in STAD and LUSC, but favorable associations in BRCA, KIRC, PRAD and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify BRCA as the clearest survival context for RPL10P17 RNA expression.
This table summarizes RPL10P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL10P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10P17 shows lower tumor expression in BRCA and higher tumor expression in PRAD and KIRC. The PRAD box plot shows higher RPL10P17 RNA expression in tumor versus normal tissue (log2 FC = +0.093, t-test p = .002).
This table shows molecular features associated with RPL10P17 in patient tissues and cancer cell lines. In patient samples, RPL10P17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
